RECURRENT COLORECTAL CARCINOMA
Clinical trials for RECURRENT COLORECTAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT COLORECTAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT COLORECTAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack shows promise for tough colorectal cancer
Disease control OngoingThis study tests a combination of two targeted drugs (encorafenib and cetuximab) plus an immunotherapy (nivolumab) in people with a specific type of advanced colorectal cancer (BRAF V600E mutation) that is stable (MSS) and has spread or can't be removed by surgery. The goal is to…
Matched conditions: RECURRENT COLORECTAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…
Matched conditions: RECURRENT COLORECTAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT COLORECTAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 07:00 UTC